mRNA Residual DNA Template Analysis Service
Overview
In the rapidly evolving landscape of the therapeutic nucleic acid development platform, the production of high-purity messenger RNA (mRNA) is paramount. A critical stage in mRNA-based vaccine development involves the in vitro transcription (IVT) process, where a DNA template is used to synthesize the RNA strand. However, the presence of residual DNA templates in the final product poses significant safety risks, including potential immunogenicity and genomic integration. As part of a comprehensive mRNA structural characterization, CD BioGlyco provides highly sensitive mRNA residual DNA template analysis services. Our solutions ensure that process-related impurities are strictly monitored and controlled according to the rigorous standards set.
Key Technologies
- Quantitative Polymerase Chain Reaction (qPCR)
This is the industry gold standard for the sensitive detection and quantification of residual DNA. By using sequence-specific primers and fluorescent probes, qPCR allows for the real-time monitoring of DNA amplification, providing a wide dynamic range and the ability to detect picogram-level contaminants within complex mRNA matrices. - Digital Polymerase Chain Reaction (dPCR)
For projects requiring absolute quantification without the need for a standard curve, dPCR (including droplet digital PCR, ddPCR) offers unparalleled precision. By partitioning the sample into thousands of individual micro-reactions, dPCR provides superior tolerance to PCR inhibitors and exceptional accuracy for low-copy number detection. - Fluorometric Assay Systems
Utilizing high-sensitivity fluorescent dyes that specifically bind to double-stranded DNA (dsDNA), we provide rapid screening for total residual DNA content. This method is often used as a complementary approach to sequence-specific PCR methods for broader impurity profiling.
Precision mRNA Residual DNA Template Analysis
As a specialized component of our mRNA structural characterization services, CD BioGlyco offers a multi-faceted approach to residual DNA analysis. We recognize that mRNA-based vaccine development requires more than just standard testing; it demands a deep understanding of the interplay between the RNA product and the remaining DNA fragments. Our service scope includes:
- Template-Specific Quantification: Development of customized qPCR/dPCR assays targeting the specific plasmid or linear DNA template used in your IVT process.
- Fragment Size Analysis: Assessment of the size distribution of residual DNA to ensure fragments are below the regulatory threshold.
- Host Cell DNA (hcDNA) Testing: If applicable, we monitor for residual DNA originating from the host cells used for plasmid production (e.g., E. coli).
- Enzymatic Digestion Efficiency Verification: Evaluating the performance of deoxyribonuclease I (DNase I) treatment during the purification workflow to optimize your manufacturing process.
Workflow
Project Consultation and Design
Our experts collaborate with you to define the target DNA sequences, required sensitivity levels, and the specific regulatory context of your mRNA therapeutic or vaccine candidate.
Sample Preparation and RNA Removal
To prevent interference, the mRNA sample undergoes optimized preparation. This often involves specialized extraction techniques or the use of ribonuclease (RNase) to remove the high-background RNA, ensuring the residual DNA is accessible for detection.
Assay Development and Optimization
We design and synthesize high-specificity primers and probes. Each assay is rigorously tested for its limit of detection (LOD) and limit of quantitation (LOQ) using standard reference materials.
Precision Instrumentation Analysis
Samples are loaded onto our high-throughput qPCR or dPCR platforms. We include negative controls, positive controls, and a series of known standards to ensure the validity of every run.
Advanced Data Processing
Raw fluorescent signals are converted into quantitative data. Our bioinformaticians perform detailed statistical analysis, assessing linearity, spike recovery, and repeatability to ensure data integrity.
Comprehensive Technical Reporting
Clients receive a detailed report including experimental parameters, quantification results, fragment size profiles, and a summary of compliance with target specifications.
Publication Data
DoI: 10.1089/hum.2023.006
Journal: Human Gene Therapy
IF: 4.8
Published: 2023
Results: This study develops a droplet digital PCR (ddPCR) assay targeting 18S rRNA genes to quantify residual host cell DNA in recombinant adeno-associated virus (rAAV) products, a critical quality control step due to infection and oncogenicity risks. Two primer pairs amplifying 116-bp and 247-bp amplicons were used, with copy numbers converted to mass concentration via reference genes (EIF5B, DCK, HBB). HEK293 genomic DNA spiking experiments showed 88.6-97.9% recovery. The assay detected 2.67-7.41 pg/109 vg of host cell DNA in rAAV preparations, with 58.9-69.3% being DNase-resistant. It also enabled assessing DNA size distribution. Results demonstrate the ddPCR method's feasibility for quantifying residual host cell DNA and its size, supporting rAAV product safety and quality control.
Fig.1 Effect of the digestion of HEK293 genomic DNA on ddPCR. (Higashiyama, et al., 2023)
Applications
mRNA Vaccine Development
Essential for meeting safety standards in the production of mRNA-based vaccines against infectious diseases or personalized cancer vaccines, ensuring residual DNA is within the 10 ng/dose limit.
Manufacturing Process Optimization
Enables developers to evaluate the effectiveness of DNase I digestion and chromatography-based purification steps, allowing for the refinement of upstream and downstream manufacturing protocols.
Gene Substitution Therapy
Supports the development of mRNA therapeutics for rare genetic disorders by providing high-precision impurity analysis required for long-term safety and efficacy assessments.
Preclinical Safety Assessment
Facilitates the evaluation of potential genotoxicity and immunogenicity risks in animal studies by accurately quantifying the levels of process-related DNA contaminants in early-stage candidates. Advantages
Advantages
Exceptional Detection Sensitivity
Our platforms achieve picogram-level sensitivity, allowing for the detection of trace DNA templates that traditional methods might miss, ensuring product safety.
Tailored Assay Development
We do not offer "one-size-fits-all" solutions; our team designs custom primers and probes specific to your unique plasmid sequences, ensuring maximum specificity and no cross-reactivity.
Comprehensive Data Analysis
Beyond simple quantification, we provide expert interpretation of result patterns, helping you troubleshoot purification issues and understand the molecular profile of your mRNA product.
Advanced Technological Suite
By offering both qPCR and dPCR, CD BioGlyco provides the flexibility to choose between high-throughput screening and the absolute precision of digital quantification for complex samples.
Frequently Asked Questions
Customer Review
Their dPCR-based residual DNA analysis was instrumental in proving the efficiency of our new purification protocol. The precision was far beyond what we could achieve in-house.
— A.T., Senior Researcher
Their ability to design custom primers for our specific plasmid template saved us weeks of development time. The report was thorough and ready for submission.
— M.G., Director of CMC
They didn't just provide numbers; they helped us understand why we were seeing certain fragment size distributions, which led to a significant improvement in our DNase I treatment step.
— T.R., Principal Scientist
Associated Services
With cutting-edge qPCR and dPCR technologies, custom assay design, and deep expertise, CD BioGlyco is your ideal partner for navigating the complexities of mRNA therapeutic characterization. Please feel free to contact us for detailed information on our services or to request a formal quotation.
Reference
- Higashiyama, K.; et al. Quantitation of residual host cell DNA in recombinant adeno-associated virus using droplet digital polymerase chain reaction. Human Gene Therapy. 2023, 34(11-12): 578-585. (Open Access)